An Open-label, Phase I/II Study of the Pan-immunotherapy in Patients With Relapsed/Refractory Ovarian Cancer
Status:
Recruiting
Trial end date:
2022-10-30
Target enrollment:
Participant gender:
Summary
Ovarian cancer is the most lethal gynecological cancer and the 5th leading cause of cancer
death in women. Platinum chemotherapy has been widely adopted as a standard treatment for
advanced ovarian cancer, the response rates in patients with relapsed/refractory ovarian
cancer is unacceptably low. PD-1 blockade has been developed to a new class of cancer
immunotherapy that could restore an adequate immunosurveillance against the neoplasm and
enhance T-cell-mediated anticancer immune responses. Manganese has been confirmed to activate
antigen-presenting cells and function as mucosal immunoadjuvants in pre-clinical studies.
This two-arm, phase I/II study is designed to assess the safety and efficacy of combined
therapy of anti-PD-1 antibody and chemotherapy with or without Manganese priming.